Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, describes an approach to combine chimeric antigen-receptor T-cells (CAR-Ts) with bispecific antibodies to improve patient outcomes. Using different adapters such as bispecific antibodies binding to both a CAR-T and a target antigen, it is possible to target several antigens in parallel or sequentially. In addition, the short half-life of bispecific antibodies enables CAR-Ts to be switched on and off easily, thereby improving the tolerability of CAR-Ts. Early data is suggesting this as a promising approach, but it is necessary to further evaluate it in a larger number of patients. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

свернуть